


# APC/Fire™ 750 anti-human CD134 (OX40)


|                         |   |
|-------------------------|---|
| <b>Catalog # /</b>      | 2350160 / 100 tests   |
| <b>Size:</b>            | 2350155 / 25 tests  |
| <b>Clone:</b>           | Ber-ACT35 (ACT35)   |
| <b>Isotype:</b>         | Mouse IgG1, κ   |
| <b>Immunogen:</b>       | HTLV 1-transformed HUT 102 cells  |
| <b>Reactivity:</b>      | Human, Other  |
| <b>Preparation:</b>     | The antibody was purified by affinity chromatography and conjugated with APC/Fire™                  |
| <b>Formulation:</b>     | Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and 0.2% (w/v) BSA (origin USA). |
| <b>Workshop Number:</b> | 750 under optimal conditions.   |
| <b>Concentration:</b>   | Lot-specific  |



PHA-stimulated (3 days) human peripheral blood lymphocytes were stained with CD3 FITC and CD134 (clone Ber-ACT35) APC/Fire™ 750 (top), or mouse IgG1, κ isotype control (bottom).

## Applications:

|                           |   |
|---------------------------|---|
| <b>Applications:</b>      | Flow Cytometry  |
| <b>Recommended Usage:</b> | Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood. |



|                           |   |
|---------------------------|---|
| <b>Application Notes:</b> | <p>* APC/Fire™ 750 has a maximum excitation of 650 nm and a maximum emission of 787 nm.</p> <p>Additional reported applications (for the relevant formats) include: Western blotting<sup>1</sup>, immunoprecipitation<sup>1</sup>, immunohistochemical staining<sup>2,3</sup> of paraffin embedded<sup>7</sup> and frozen tissue sections, ELISA<sup>4</sup>, and functional assay<sup>5</sup>.</p> |
|---------------------------|---|

Human peripheral blood lymphocytes were stained with anti-human CD4 FITC and anti-human CD25 (clone M-A251) Spark YG™ 581 (left) or anti-human CD4 FITC only (right).

|                                |   |
|--------------------------------|---|
| <b>Application References:</b> | <ol style="list-style-type: none"> <li>1. Latza U, et al. 1994. <i>Eur. J. Immunol.</i> 24:677. (WB, IP)</li> <li>2. Durkop H, et al. 1995. <i>Brit. J. Haematol.</i> 91:927. (IHC)</li> <li>3. Durkop H, et al. 1997. <i>Brit. J. Haematol.</i> 98:863. (IHC)</li> <li>4. Willett B, et al. 2007. <i>J. Virol.</i> 81:9665. (ELISA)</li> <li>5. Li M and Zhang Y. et al. 2005. <i>Cell. Mol. Immunol.</i> 2:467. (FA)</li> <li>6. Gloviczki ML, et al. 2012. <i>Clin. J. Am. Soc. Nephrol.</i> 8:546. <a href="#">PubMed</a></li> <li>7. Domingos PL, et al. 2012. <i>An. Bras. Dermatol.</i> 87:851. (IHC)</li> </ol> |
|--------------------------------|---|

**Description:** CD134, also known as OX40 and TNFRSF4, is a 50 kD type I transmembrane glycoprotein. It is a member of the TNF receptor family. OX40 is expressed on activated T lymphocytes including Th1, Th2, Th17, and Treg cells. The interaction of OX40 with OX40L results in B cell proliferation and antibody secretion, regulation of primary T cell expansion, and T cell survival. OX40 influences the size of the T cell memory pool and regulation of CD4<sup>+</sup> T cell tolerance.

**Antigen**  
**References:**

1. Smith CA, *et al.* 1994. *Cell*. 76:959.
2. Chen AL, *et al.* 1999. *Immunity*. 11:689.
3. Croft M. 2010. *Annu. Rev. Immunol.* 28:57.
4. Ruby CE, *et al.* 2009. *J. Immunol.* 183:5079.
5. Klinger M, *et al.* 2009. *J. Immunol.* 182:4581.